Description of Collaborative Activity: |
The Working Group focuses on potential MERS-CoV countermeasures, to include therapeutics (antivirals, monoclonals and others) and vaccines. The working group has been asked to assess the following:
a) inventory of what potential therapeutics (and vaccines) are under development/investigation by what groups
b) how far along are they in pre-clinical development (in-vitro, animal studies/mice/non- human primates) and what data are available
c) timelines for animal studies, scale-up, when could human trials be started – phase 1, phase 2, open-label studies
d) regulatory issues for IND, EUA, and clinical studies, safety issues
e) prioritization for clinical trials based upon pre-clinical data and scientific assessment of available data |
Type of Collaborative Activity: |
Committee, Advisory Group, or Work Group
|
